Nuvectis in-licenses ex-China rights to two clinical-stage compounds from Haisco for up to $1.46B

Nuvectis Pharma, Inc.

• Upfront and near-term payments total up to $40M; potential milestones up to $1.421B plus tiered royalties.
• NXP100 (CFBi) has two MAAs under review in China for PNH; Ph3 ongoing in IgAN; Ph2 in LN.
• NXP200 (paradox-breaker BRAFi) showed >40% response in gliomas and durable responses in multiple tumors; Phase 1b ongoing.
• Deal transforms Nuvectis into late-stage clinical company with two best-in-class potential assets.
• Agreement subject to financing conditions to ensure sufficient capital for product development.